How 'The Big Fat Truth' Cured A Local Woman's Type 2 Diabetes

How 'The Big Fat Truth' cured a local woman's Type 2 diabetes

Jill Brunkhardt didn’t know what to expect.
As a single mom and busy South Bay community advocate through her work as Chevron's public affairs representative, she was having trouble losing weight, no matter how much she exercised. Two years ago, she was diagnosed with type 2 diabetes.
Her doctor didn't tell her to lose weight or change her lifestyle. "It was just—take the medication," she said.
So, she responded to a Facebook post seeking type 2 diabetics for a new T.V. show based on JD Roth's book "The Big Fat Truth." What Brunkhardt found was what she calls a life changing experience.
“I knew we would do a plant-based diet, but I didn’t know what that really meant. Day one, they told me I would not be eating dairy or meat protein. I went through significant detox from not putting that in my body, but after the first five or six days, I started to feel really good, and my sugar levels were stabilizing, in fact they were getting lower after eating.”
Then after only ten days on the program, Brunkhardt's doctor took her off her diabetic medication entirely.
Brunkhardt's journey along other type 2 diabetics airs on Sunday, July 16, at 8 p.m. on Z Living. "The Big Fat Truth" is Manhattan Beach-based Roth's latest foray into the weight loss reality genre. He is former executive producer of NBC's "The Biggest Loser" and ABC's "Extreme Weight Loss."
But "The Big Fat Truth," the book and the show, is dedicated to the well-being of participants and viewers alike, according to Roth. Leading participants on a healthy, plant-based diet is one thing, he said, but also helping Continue reading

Rate this article

Total 1 ratings

Researchers Make Progress on a Pill to Stop Type 2 Diabetes

Pharmaceutical researchers are one step closer to making a pill that can reverse the symptoms of type 2 diabetes. They published their research in the journal Nature Chemical Biology.
Diabetes and its complications are a major issue within the United States and abroad. In 2012, the American Diabetes Association reported that 29.1 million Americans, or 9.3 percent of the population, lived with diabetes.
Various factors, including age and obesity, can cause a person’s body to stop responding to the blood-sugar regulating hormone called insulin. Current drugs for type 2 diabetes work by eliminating glucose from a person’s bloodstream. These prescriptions can help a great deal, but they’re not a cure, and the side effects can be nasty.
The authors of the new study wondered if they could address the problem farther up in the pipeline by convincing the body to respond to insulin again. They created a compound that blocks the release of a chemical called low molecular weight protein tyrosine phosphatase (LMPTP), an enzyme that’s previously been implicated in insulin resistance.
They gave the drugs to a group of obese, diabetic mice by mouth, once a day for four weeks, all the time monitoring the rodents’ blood sugar and insulin resistance. In that short time, the animals’ bodies began responding to insulin and their blood sugar began to stabilize. The mice experienced no side effects.
The next step will be testing the drug in other animals, and then in people. Lead researcher Stephanie Stanford of the University of California, San Diego, is hopeful the pill’s success Continue reading

New diabetes treatment teaches rogue immune cells to behave

FRIDAY, July 14, 2017 -- A treatment targeting wayward immune cells in people with type 1 or type 2 diabetes may help even years later, a new study finds.
For the treatment, researchers take blood from a person with diabetes and separate out the immune system cells (lymphocytes). They briefly expose those cells to stem cells from umbilical cord blood from an unrelated infant. Then they return the lymphocytes to the patient's body.
The researchers have dubbed this treatment "stem cell educator therapy," because when exposed to the stem cells, the errant lymphocytes seem to re-learn how they should behave.
"Stem cell educator therapy is a safe approach" with long-term effectiveness, said the study's lead author, Dr. Yong Zhao. He's an associate scientist at Hackensack University Medical Center in New Jersey.
Type 1 diabetes, an autoimmune disease, occurs when the body's immune system cells mistakenly attack the insulin-producing, or beta, cells in the pancreas. This leaves people with type 1 diabetes with little to no insulin. They need insulin injections to survive.
Researchers have long thought that any cure for type 1 diabetes would have to stop the autoimmune attack, while regenerating or transplanting beta cells.
But Zhao and his team developed a new approach to the problem -- educating the immune cells that had been destroying beta cells so they stop attacking.
In type 2 diabetes, Zhao said immune cell dysfunction is responsible for chronic inflammation that causes insulin resistance. When someone is insulin resistant, their body's cells can't properly use insulin to us Continue reading

Fractyl Is on a Mission to Cure Type 2 Diabetes

Today we are proud to announce our investment in Fractyl, a medical technology company co-founded by Harith Rajagopalan and Jay Caplan. Fractyl is pioneering a procedural therapy that can reverse insulin resistance and resulting metabolic diseases including type 2 diabetes and nonalcoholic steatohepatitis (NASH). The potential here is absolutely life changing, going beyond simply managing diseases like type 2 diabetes to actually curing them.
Harith and I have known each other since we were undergraduates in college. For as long as I’ve known him, I’ve admired his integrity as much as his intellect, and I’m proud to call him a friend. I’ve followed his career and Fractyl’s progress over the past few years, watching closely from the sidelines. When Harith and I met for dinner a couple months back, I knew I had to be a part of his mission.
After completing his residency and fellowship in cardiology at Brigham and Women’s Hospital at Harvard, Harith started looking for better ways to help his patients. While the gut’s central role in controlling metabolism has long been overlooked, Harith discovered that metabolic diseases could be rooted in the intestines.
After much passion-driven experimentation and research, Harith and Jay invented a minimally invasive and scalable, device-based procedure called Revita™ DMR that directly treats a portion of the small intestine (or duodenum) that is altered by modern diets. An outpatient procedure that takes under an hour, Revita™ DMR aims to rejuvenate the lining of the duodenum and reverse insulin resistance, thereby cor Continue reading

Gaston 5-year-old lobbying Congress for Type 1 diabetes cure

He’s only 5 years old, but he’s preparing to advocate for juvenile diabetes research before Congress.
Miles Bone spent Wednesday morning engaged in a wild, water war with his pre-kindergarten classmates at Gaston Day School to celebrate the end of the year. After toweling off, he readied to eat a chicken nuggets lunch from Chick-fil-A with everyone.
But first, he had to prick his finger with a needle to test his blood glucose level, a ritual he must repeat several times each day as a Type 1 diabetic. He entered his glucose number into an insulin pump—which he wears basically 24/7—that injects him with the correct amount of insulin through a tube attached to his arm to keep his blood glucose stable after eating.
“We talked about last night how he wants to show people what it’s like to have Type 1 diabetes because a lot of people don’t know,” said Sara Bone, Miles’s mother. “A lot of people don’t understand what Type 1 diabetes is and how much it affects his life and how hard he has to work to take care of himself.”
Type 1 diabetes, also known as juvenile diabetes, is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone people need to get energy from food. Children and adults can be diagnosed suddenly at any age. It cannot be prevented and there is no cure.
Miles, who lives in Dallas with his parents and older brother, will advocate for Type 1 diabetes research on Capitol Hill in late July. He applied and was selected to be part of a delegation of about 160 children from each U.S. state and several countries represent Continue reading